Prophy dex with glofitamab (4 mg after 1st glofi & bid for 3 days after C1D8, C1D15, C2D1) with reduction in CRS from 63% in trial to 32%, all G1-2. Moving towards outpatient glofi. #18ICML #lymsm

📢Final BELLINI results at 45.6 months follow-up show no overall survival benefit of venetoclax in the general relapsed or refractory multiple myeloma population. Post-hoc analyses suggest benefits are limited to biomarker-positive subgroups. 👇 shorturl.at/bwOYn

1/ Nice myeloma #MMsm work in Blood Advances by Kim Noopur Raje Andrew Yee, MD et al: For NDMM plus severe cast nephropathy (e.g., peri-dialysis), rapid dara initiation works quite well. Inpatient dara is 💵, but I'd argue PLEX even more expensive plus more burdensome for pt!

1/ Excellent Blood Journals Portfolio work by Claveau Mayo Myeloma et al. If 2+ #MMsm parameters in wrong direction at once, almost certainly PD. 🤞🏻coming to IMWG criteria soon, and I love it! 1️⃣ Less time tox & anxiety of bringing pt back for 🩸x2 2️⃣ Quicker TTNT if Tx not working...

🎯 At #IMS25, we spoke with Matthew M. Lei, PharmD, BCOP of MassGeneral News on his poster exploring elranatamab consolidation after ide-cel in relapsed/refractory multiple myeloma🔬💉 Check back to our website for the latest conference updates! onclive.com/conference/imw

CONGRESS | IMS 2025 | PRESENTATION Benjamin Puliafito, Massachusetts General Hospital, discussed toxicity management, infection management, secondary cancers and delayed neurotoxicity; focussing on BCMA CAR-T cell toxicities and management strategies. Follow our live feed on the

The 2025 LBCL Guidelines are out ! Fantastic work made by the European Hematology Association Cc C. Thieblemont doi.org/10.1002/hem3.7…

#Myeloma Paper of the Day: IFM2017-03 trial of Revlimid/Darzalex w/ 2 cycles of dex versus triplet w/ continuous dex finds DRAMATICALLY reduced progression risk (53.4 mos (95% CI 35.3-not reached) vs. 22.5 mos (HR 0.51, 95% CI 0.37-0.70, p<0.0001)): pubmed.ncbi.nlm.nih.gov/41038184/. #mmsm

Just out in the Journal of Clinical Oncology! Journal of Clinical Oncology A paradigm changing paper on MGUS and Smoldering Myeloma Francesco Maura And it’s Open Access!! ascopubs.org/doi/10.1200/JC… KEY FINDINGS: 1) We identify for the first time myeloma defining genomic events to differentiate

Updated mSMART guidelines on treatment of newly diagnosed myeloma. Major change: For standard risk myeloma, doublet maintenance (lenalidomide plus anti CD38) recommended if MRD+ post transplant. msmart.org/mm-treatment-g…

🚨Just out Clinical Cancer Research 🚨 V proud of our manuscript on polatuzumab efficacy by cell of origin in DLBCL We show COO by Hans predicts pola sensitivity in 740 pts Pts w R/R non-GCB DLBCL have higher ORR, CRR & PFS Massive thanks David Russler-Germain, MD/PhD & collabs! aacrjournals.org/clincancerres/…

Monitoring ctDNA in aggressive B-cell lymphoma: a prospective correlative study of ctDNA kinetics and PET-CT metrics | Blood Advances | American Society of Hematology ashpublications.org/bloodadvances/…

With almost 1,000 myeloma-related communications at this ASH #ASH25, it is now impossible to come up with a “Top 10 abstracts” list. Here are 10 topics I found interesting and speak to the continued progress in the #mmsm field on bright display this year

MGUS - Up to date and comprehensive NEJM Review that I co-authored with Shaji Kumar NEJM Check out the figures! nejm.org/doi/abs/10.105…

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia | New England Journal of Medicine nejm.org/doi/full/10.10…

#ASH25 #mmsm ASH Choosing the optimal maintenance strategy in multiple myeloma Noopur Raje ➡️ashpublications.org/hematology/art…

Just published: RWE patterns in DLBCL tx show a rapidly evolving landscape. Despite progress, outcomes still decline with each LOT. No clear standard after CAR T—sig unmet need for effective, durable options. #DLBCL Fred Hutch Cancer Center pubmed.ncbi.nlm.nih.gov/41345384/

How specific are therapeutic monoclonal antibodies, really? In our new paper, Yile Dai led a collaboration with Adimab to profile 174 FDA-approved and clinical-stage mAbs against 6,172 human extracellular proteins. What we found surprised us.🧵 sciencedirect.com/science/articl…

Check out the fully updated myelomarisk.com The one stop site to simply enter variables and calculate current risk stratification of Myeloma Smoldering Myeloma MGUS Amyloidosis Waldenstroms Link: eatoure.github.io/#/ E. Amadou Touré Shaji Kumar Francesco Maura

Check our recent paper Blood Cancer Journal UAMS Myeloma Center UTSW Simmons Cancer Center #mmsm Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients ➡️n=177 ➡️CMV reactivation occurs in ~22% of teclistamab-treated myeloma patients ➡️90% are